OC
OCEA.US Ocean Biomedical Inc.
- Market cap
- USD 23.2K
- P/E
- -
- P/B
- 100.67x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2025.
Is OCEA.US undervalued?
Graham numberThe Graham number of Ocean Biomedical Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ocean Biomedical Inc. fundamental analysis
No fundamental analysis for Ocean Biomedical Inc. yet.
Ocean Biomedical Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ocean Biomedical Inc.
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company's oncology product candidates include OCX-253 anti-Chi3l1 Single-target mAb and OCX-410 anti-Chi3l1/PD-1 Bi-specific antibody for the treatment of non-small cell lung cancer; and OCX-909 anti-Chi3l1/CTLA-4 Bi-specific antibody to treat glioblastoma multiforme. Its fibrosis product cand…
Full company profileOcean Biomedical Inc. financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ocean Biomedical Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -232K | -1.65M | -62.3M | -2.48M | -10.2M | -3.80M | -3.83M |
| EBITDA | -232K | -1.65M | -62.3M | -958K | -113M | -7.43M | -31.6M |
| Net Income | -232K | -1.65M | -62.3M | 565K | -114M | -3.30M | -33.0M |
| EPS | -0.01 | -0.08 | -4.71 | 0.03 | -3.30 | -0.12 | -1.20 |
| Balance Sheet | |||||||
| Total Assets | 0.00 | 386K | 109M | 111M | 5.50M | 902K | 1.58M |
| Total Liabilities | 232K | 2.27M | 3.40M | 6.61M | 96.3M | 98.5M | 94.0M |
| Shareholders' Equity | -232K | -1.89M | 105M | 104M | -90.8M | -97.6M | -92.4M |
| Cash & Short-term Investments | - | 0.00 | 1.08M | 328K | 4.00K | 224K | 777K |
| Total Debt | - | - | - | 2.15M | 12.1M | 16.3M | 9.35M |
| Cash Flow | |||||||
| Operating Cash Flow | -64.0K | -64.0K | -1.05M | -747K | -9.43M | -4.18M | -1.42M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 3.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 0.00 | -64.0K | -1.05M | -747K | -9.43M | -4.18M | -1.42M |
| Ratios | |||||||
| ROE | - | - | -59.2% | 0.5% | - | - | - |
| ROA | - | -428.2% | -57.4% | 0.5% | -2,080.8% | -366.0% | -2,083.4% |
| Debt to Equity | - | - | - | 0.02x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ocean Biomedical Inc. dividends
Ocean Biomedical Inc. has not paid dividends in the last 6 fiscal years.
Who owns Ocean Biomedical Inc.
- Insiders 10.31%
- Institutions 0.00%
- Public & others 89.69%
- Shares outstanding 232M
- Free float 208M
Ocean Biomedical Inc. company profile
- Company name
- Ocean Biomedical Inc.
- Ticker
- OCEA.US
- Exchange
- USA Stocks
- Listed since
- Nov 8, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- December
- Address
- 55 Claverick Street, Providence, RI, United States, 02903
- Phone
- 401 444 7375
- Website
- oceanbiomedical.com
About Ocean Biomedical Inc.
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company's oncology product candidates include OCX-253 anti-Chi3l1 Single-target mAb and OCX-410 anti-Chi3l1/PD-1 Bi-specific antibody for the treatment of non-small cell lung cancer; and OCX-909 anti-Chi3l1/CTLA-4 Bi-specific antibody to treat glioblastoma multiforme. Its fibrosis product candidates consist of OCF-203 anti-Chit1 small molecule for the treatment of idiopathic pulmonary fibrosis (IPF) and hermansky-pudlak syndrome (HPS). The company's infectious diseases product candidates for malaria include the ODA-570 vaccine for the prevention of P. falciparum infection; ODA-611 anti-PfGARP mAb for the treatment of Symptomatic P. falciparum infection; and ODA-579 anti-PfGARP small molecule for the treatment of Symptomatic P. falciparum infection. It has license agreement with Elkurt, Inc. for FRG Antibody, bi-specific antibody anti-CTLA4, bispecific (FRG)x anti-PD-1 (FRGxPD-1), chit1 small molecule antifibrotic, and malaria small molecules and antibodies. The company was founded in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. is a subsidiary of Poseidon Bio, LLC.
Ocean Biomedical Inc. management
2- Dr. Inderjote Kathuria M.B.A., M.D.Chief Strategy Officer · born 1968
- Dr. Chirinjeev Baboo Kathuria M.B.A., M.D.Founder & Executive Chairman of the Board · born 1965